Hemab's IPO Doubled on Day One. The Blood Disease Bet Wall Street Couldn't Resist.

Behind sutacimig sits HMB-002, a monovalent antibody targeting Von Willebrand disease (the most common inherited bleeding disorder). Early Phase 1 data showed it could boost key clotting factors and extend their half-life, potentially becoming a first-in-class prophylactic therapy. A third candidate, HMB-003, is expected to be unveiled sometime this year.

From Danish Lab to Nasdaq Darling

Hemab's origin story reads like a classic biotech bootstrap. Founded in 2020 by a team of five founders including Johan Henrik Faber and led by CEO Benny Sorensen, the company licensed antibody technologies from two Danish pharma powerhouses: Novo Nordisk and Genmab. Novo Seeds, the early-stage investment arm of Novo Holdings, provided the initial seed funding.

The venture rounds escalated quickly. A $55 million Series A in July 2021 brought in Novo Holdings, HealthCap, and RA Capital Management. By the Series C, the roster had expanded to include Sofinnova Partners, Avoro Capital Advisors, a large sovereign wealth fund, and a major long-only asset manager. That round raised $157 million, enough to push both lead candidates toward registration studies.

By the time the IPO priced, Hemab's market cap sat at roughly $795 million. After that first-day surge, it's considerably higher.

The IPO Window Is Wide Open (For Now)

Hemab wasn't the only biotech making a splash. Avalyn Pharma also debuted on April 30, raising $300 million for its inhaled lung therapies after upsizing from a $182 million target. Earlier in April, Kailera Therapeutics pulled off the largest biotech IPO of 2026, raising north of $625 million for its obesity program.

Zoom out further and the picture gets even more striking. Q1 2026 saw biotechs raise $1.7 billion through IPOs, the strongest quarter since the 2021 boom. The median IPO size hit $287.5 million, roughly double the prior year. Industry watchers now project 30 to 35 biotech IPOs for the full year.

For companies with solid clinical data and a clear regulatory path, the window is as inviting as it's been in years. The question is always the same: how long does it stay open?

Why This One Stands Out

Plenty of biotechs go public with impressive fundraising numbers. What makes Hemab interesting is the combination of factors working in its favor.

First, rare disease is Wall Street catnip. Orphan drug designations mean less competition, premium pricing, and a clear regulatory pathway. The broader rare hemophilia factors market is projected to grow at a 6.4% clip through 2030.

Second, the clinical data is real. Breakthrough Therapy Designation isn't handed out for wishful thinking. It requires evidence of meaningful improvement over what's already available, and for Glanzmann thrombasthenia patients, there isn't much available.

Third, the investor pedigree is stacked. When Novo Holdings backs you from seed stage through IPO, it sends a message. The sovereign wealth fund and long-only investors in the Series C added institutional credibility that likely smoothed the IPO roadshow.

The 89% first-day gain is flashy, but it also means Hemab left a lot of money on the table. Some might argue they could have priced higher. Then again, having your stock nearly double is one heck of a way to start a relationship with public market investors. It creates goodwill, loyalty, and a cushion if clinical timelines hit a bump.

What's Next

Hemab's IPO proceeds should fund the push toward pivotal trials for both sutacimig and HMB-002. The reveal of HMB-003's target could add another catalyst in the coming months. For a company that didn't exist five years ago, the trajectory has been remarkably efficient: seed funding to a $795 million IPO valuation in about five years, with two clinical-stage assets and a Breakthrough designation in hand.

The biotech IPO market is running hot. Hemab just turned the heat up another notch.